A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT00777309. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Study of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, placebo-controlled, double blind phase 2 study designed to compare treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small cell lung cancer. The study will enroll patients who have had one prior chemotherapy regimen (other than erlotinib) for NSCLC.
Study identification
- NCT ID
- NCT00777309
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Enrollment
- 167 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2008 (Type not available)
- Primary completion
- May 2011 (Actual)
- Completion
- Aug 2011 (Actual)
- Last update posted
- Feb 28, 2013
2008 – 2011
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Burbank | California | 91505 | — |
| Not listed | Santa Monica | California | 90404 | — |
| Not listed | Torrington | Connecticut | 06790 | — |
| Not listed | Jacksonville | Florida | 32204 | — |
| Not listed | Atlanta | Georgia | 30309 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Batesville | Indiana | 47006 | — |
| Not listed | Indianapolis | Indiana | 46107 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Worcester | Massachusetts | 01608 | — |
| Not listed | Charlotte | North Carolina | 28204 | — |
| Not listed | Canton | Ohio | 44718 | — |
| Not listed | Corpus Christi | Texas | 78410 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | Dallas | Texas | 75390 | — |
| Not listed | Houston | Texas | 77024 | — |
| Not listed | Salt Lake City | Utah | 84114 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00777309, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 28, 2013 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00777309 live on ClinicalTrials.gov.